Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating recently and
Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating recently and
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Edwards Lifesciences (EW – Research Report), Tandem Diabetes Care (TNDM – Research Report) and BioMarin Pharmaceutical (BMRN – Research Report).
Edwards Lifesciences (EW)
TD Cowen analyst Josh Jennings maintained a Hold rating on Edwards Lifesciences today and set a price target of $70.00. The company’s shares closed last Thursday at $65.37.
According to TipRanks.com, Jennings is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Edwards Lifesciences with a $77.50 average price target, a 19.5% upside from current levels. In a report issued on October 1, Evercore ISI also maintained a Hold rating on the stock with a $70.00 price target.
See the top stocks recommended by analysts >>
Tandem Diabetes Care (TNDM)
Tandem Diabetes Care received a Hold rating from Goldman Sachs analyst David Roman today. The company’s shares closed last Thursday at $40.46.
According to TipRanks.com, Roman is a 3-star analyst with an average return of
Tandem Diabetes Care has an analyst consensus of Strong Buy, with a price target consensus of $56.50, which is a 37.6% upside from current levels. In a report issued on September 23, Morgan Stanley also assigned a Hold rating to the stock with a $45.00 price target.
BioMarin Pharmaceutical (BMRN)
Barclays analyst Gena Wang maintained a Buy rating on BioMarin Pharmaceutical today and set a price target of $86.00. The company’s shares closed last Thursday at $68.16, close to its 52-week low of $67.75.
According to TipRanks.com, Wang is a 4-star analyst with an average return of
BioMarin Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $105.95, implying a 52.3% upside from current levels. In a report issued on September 25, Truist Financial also maintained a Buy rating on the stock with a $90.00 price target.
Read More on EW:
התחילו שותפות חדשה למחקר עם CAMP4 Therapeutics. המטרה היא לפתח תרופות חדשות שמגבירות את רמות החלבון על ידי התמקדות ברצפי RNA רגולטוריים. רצפים אלו חשובים משום שהם שולטים באופן פעולת
CAMP4 Therapeutics announced a new research collaboration with BioMarin Pharmaceutical Inc. aimed at advancing novel therapeutics that increase protein levels by targeting regulatory RNA sequences, which are key elements controlling
Truist Financial analyst Joon Lee maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) yesterday and set a price target of $90.00. The company’s shares closed yesterday at